Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Comparison of circulating tumor cells and AR-V7 as clinical biomarker in metastatic castration-resistant prostate cancer patients

Abstract Biomarker in metastatic castration resistant prostate cancer (mCRPC) treatment are rare. We aimed to compare the clinical value of circulating tumor cells (CTCs) and androgen receptor splice variant 7 (AR-V7) as biomarker in mCRPC patients undergoing androgen receptor-targeted agent (ARTA)...

Full description

Bibliographic Details
Main Authors: Katrin Schlack, Konstantin Seitzer, Neele Wüstmann, Verena Humberg, Norbert Grundmann, Julie Steinestel, Dorothee Tiedje, Kambiz Rahbar, Laura-Maria Krabbe, Martin Bögemann, Andres J. Schrader, Christof Bernemann
Format: Article
Language:English
Published: Nature Portfolio 2022-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-16094-6

Internet

https://doi.org/10.1038/s41598-022-16094-6

Similar Items